Blood Cancer and Immunotherapy

Thursday
October 7, 2021, 3:20 pm -
3:55 pm
Cell therapies transforming treatment

Watch On Demand

Session Description

More than 175,000 new cases of leukemia, lymphoma, and multiple myeloma are expected this year in the United States. Fortunately, a revolution in blood cancer treatment has arrived with immune checkpoint blockade and CAR T cell therapies providing new options for patients. Several immunotherapies are already FDA-approved, and ongoing research demonstrates even greater potential for new treatments, especially in adoptive cell therapy. Join Dr. Hearn Jay Cho of Mount Sinai Tisch Cancer Institute in a Q&A discussion about different immunotherapies used in the treatment of blood cancers and new treatments in development to bring the benefits of immunotherapy to even more patients.

Speaker(s)

Hearn Jay Cho, M.D., Ph.D.

Mount Sinai Tisch Cancer Institute

Dr. Hearn Jay Cho is an associate professor of medicine at the Icahn School of Medicine at Mount Sinai and an attending physician with the multiple myeloma service at the Mount Sinai Tisch Cancer Institute in New York. He is also the chief medical officer of the Multiple Myeloma Research Foundation. His laboratory investigates novel therapies for multiple myeloma in two areas: the interaction between myeloma and the immune system in the tumor microenvironment to better personalize immunotherapies for cancer patients, and melanoma antigen genes that are correlated with disease progression and play a critical role in treatment resistance. His team is currently conducting studies to identify novel pharmacologic strategies to inhibit these genes in myeloma. Dr. Cho received his M.D. and Ph.D. in immunology from Cornell University Medical College and did his clinical fellowship in Hematology and Medical Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

On-Demand Now Available

We are excited to announce that videos from our 2021 Cancer Research Institute (CRI) Virtual Immunotherapy Patient Summit are now available to view on demand.

The on-demand videos can be found on each session page from the agenda.